Pacing burden and clinical outcomes after transcatheter aortic valve replacement-A real-world registry report
| Autor: | Sharon Shalom Natanzon, Alexander Fardman, Nira Koren-Morag, Paul Fefer, Elad Maor, Victor Guetta, Amit Segev, Israel Barbash, Eyal Nof, Roy Beinart |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Heart Failure
Pacemaker Artificial Cardiac Pacing Artificial Stroke Volume Aortic Valve Stenosis Ventricular Function Left Transcatheter Aortic Valve Replacement Treatment Outcome Risk Factors Physiology (medical) Aortic Valve Humans Registries Cardiology and Cardiovascular Medicine Retrospective Studies |
| Zdroj: | Heart rhythm. 19(9) |
| ISSN: | 1556-3871 |
| Popis: | Conflicting data exist on the prognostic significance of permanent pacemaker (PPM) implantation after transcatheter aortic valve replacement (TAVR).The purpose of this study was to evaluate whether PPM implantation after TAVR is associated with adverse outcomes.A retrospective analysis of a cohort comprised patients enrolled in a prospective registry between 2008 and 2019. Participants were allocated into 3 groups: patients without a prior pacemaker (n = 930 [75%]), those with previous pacemaker implantation (n = 118 [10%]), and those with pacemaker implantation after TAVR (n = 191 [15%]). The primary outcome included death and heart failure hospitalizations at 1 year. Secondary outcomes included death and heart failure hospitalizations stratified by pacing burden.A total of 1239 patients underwent TAVR with a median follow-up period of 2.3 years (interquartile range 1-4 years). Patients with previous and new pacemaker implantation were older (84 [80-88], 84 [80-88], and 82 [78-86] years; P = .009) and had lower baseline left ventricular ejection fraction (50% ± 15%, 55% ± 12%, and 56% ± 12%; P.001). Patients who underwent new pacemaker implantation had higher combined outcome of death and heart failure hospitalizations (21%,12%, and 14%; P = .01). New pacemaker implantation was associated with almost twice the risk of 1-year mortality (odds ratio 1.85; 95% confidence interval 1.13-3.02; P = .014). Pacing burden, however, was not associated with the primary outcome. Furthermore, no significant difference was observed at long-term follow-up (cumulative probability to develop the primary end point at 3 years was 57% ± 2% [without PPM], 57% ± 6% [prior PPM], 54% ± 4% [new PPM]; P = .52).Pacemaker implantation after TAVR is associated with higher 1-year adverse outcome, but this attenuates over time, suggesting that competing factors may play a role. Interestingly, pacing burden is not associated with adverse clinical course. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|